FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News

Massive Judgment Against Ethicon Upheld

A California appeals court upholds $302 million of a $344 million trial court judgment against Ethicon over misleading communications about its pelvic...

Human Drugs

FDA Breakthrough Rescission on Protagonists Rusfertide

FDA tells Protagonist Therapeutics that it intends to rescind the companys breakthrough therapy designation for rusfertide and its use in treating pol...

Biologics

Merck Gets Breakthrough on Pneumococcal Vaccine

FDA grants Merck a breakthrough therapy designation for V116, an investigational 21-valent pneumococcal conjugate vaccine.

Human Drugs

AbbVie, Genmab Contacting Regulators on Cancer Drug

AbbVie and Genmab say they will open regulatory discussions on their investigational cancer drug epcoritamab, based on Phase 1/2 trial topline results...

New Guidance Promotes More Trial Diversity

FDA publishes a draft guidance updating a 2016 guidance by telling medical product sponsors what should be included in a Race and Ethnicity Diversity ...

Human Drugs

House Committee Releases McKinsey Report

The House Committee on Oversight and Reform issues a report demonstrating McKinsey & Companys conflicts of interest in working for opioid manufacturer...

Human Drugs

pH Adjuster Waiver Request Guidance

FDA publishes a draft guidance to help ANDA applicants prepare and submit pH adjuster waiver requests for specific types of drugs.

Federal Register

Gene Therapies Panel Reviews 2 bluebird BLAs

Federal Register notice: FDA announces a 6/9-10 Cellular, Tissue and Gene Therapies Advisory Committee meeting to discuss two bluebird bio BLAs.

Federal Register

Device Guides on Denture Base Screws

Federal Register notice: FDA makes available two final device-specific guidance documents for the Safety and Performance Based Pathway.

Federal Register

FDA Debars Raventos Over Falsifying Trial Data

Federal Register notice: FDA permanently debars Lisett Raventos from providing services in any capacity related to an approved or pending drug product...